-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After the publication of the book "The Rise and Fall of Multinational Pharmaceutical Enterprises", some readers asked me whether China's innovative drugs going overseas would be obstructed by foreign politics, whether Chinese innovative drugs going overseas could follow Takeda's me-too go overseas model, and what kind of Chinese innovative drugs would go overseas? Can it overtake the US? To this end, the author has thought and summarized, and wrote the following small article to share with readers
.
Will China's innovative drugs go overseas will be obstructed by politics? The answer is yes
.
In addition to the attributes of general commodities, many scholars believe that drugs also have political attributes and public attributes.
In contrast, Japan vigorously promoted drug innovation in the 1970s.
In just ten years, a large number of new chemical entities have been synthesized in Japan, and the number of new drugs approved each year is second only to the United States, Germany and other traditional innovative drug powerhouses, but the fact is These products are just me-too and me-worse, and few products have gone out of Japan
.
In the late 1980s and early 1990s, me-too companies represented by Takeda began to go abroad.
Looking at today's innovative drug companies in China, the R&D pipeline is still mostly me-too, and the products lack enough bright spots
.
These products can use the "fast-follow" strategy according to the availability of innovative drug resources in China, and make a lot of money with strong sales strength, but the United States is the country with the highest rate and degree of access to innovative drugs.
